Pharmacogenomically actionable medications in a safety net health care system

Janet S. Carpenter*, Marc B. Rosenman, Mitchell R. Knisely, Brian S. Decker, Kenneth D. Levy, David A. Flockhart

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

17 Scopus citations


Objective: Prior to implementing a trial to evaluate the economic costs and clinical outcomes of pharmacogenetic testing in a large safety net health care system, we determined the number of patients taking targeted medications and their clinical care encounter sites. Methods: Using 1-year electronic medical record data, we evaluated the number of patients who had started one or more of 30 known pharmacogenomically actionable medications and the number of care encounter sites the patients had visited. Results: Results showed 7039 unique patients who started one or more of the target medications within a 12-month period with visits to 73 care sites within the system. Conclusion: Findings suggest that the type of large-scale, multi-drug, multi-gene approach to pharmacogenetic testing we are planning is widely relevant, and successful implementation will require wide-scale education of prescribers and other personnel involved in medication dispensing and handling.

Original languageEnglish (US)
JournalSAGE Open Medicine
StatePublished - 2016
Externally publishedYes


  • Genetic polymorphism
  • Genotype
  • Patient safety
  • Pharmacoepidemiology
  • Pharmacogenetics
  • Pharmacogenomics

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Pharmacogenomically actionable medications in a safety net health care system'. Together they form a unique fingerprint.

Cite this